OD designation doesn't provide any revenue. There are other benefits in reducing the overall time to get an outcome from the FDA. If a PRV is granted that has a $ figure (about 100m USD) but those are granted only after a successful NDA in the US. The PRV is worth approximately that value, given recent sales. As a point of comparison Acadia is sitting on a PRV and NEU is entitled to 1/3 of its value (33m AUD) but NEU will also get another PRV for NNZ-2591 for Phelan McDermid Syndrome if they are ultimately successful with Phase 3.
None of this is applicable to TGA/Australian approval.
OD designation doesn't provide any revenue. There are other...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
-0.001(1.67%) |
Mkt cap ! $61.04M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.0¢ | 5.9¢ | $33.06K | 555.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 635265 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 331957 | 1 |
View Market Depth
| Last trade - 15.36pm 01/10/2024 (20 minute delay) ? |
| NTI (ASX) Chart |